Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
David L. Goode, Shivakumar Keerthikumar, Santosh Gupta, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Tori Singer, Ernest W.N. Lam, L. Fernández, E. Jiménez, Dou Zhang, Yvonne G. Lin, Richard Wenstrup, Anupama Pasam, Rodney J. Hicks, Grace Kong, Anis Hamid, Shahneen Sandhu (2023). 1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.09.2773.
Article170 days ago1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
David L. Goode, Shivakumar Keerthikumar, Santosh Gupta, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Tori Singer, Ernest W.N. Lam, L. Fernández, E. Jiménez, Dou Zhang, Yvonne G. Lin, Richard Wenstrup, Anupama Pasam, Rodney J. Hicks, Grace Kong, Anis Hamid, Shahneen Sandhu (2023). 1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.09.2773.
Article170 days ago